Clinical trials: Chronic Thromboembolic Pulmonary Disease
Chronic Thromboembolic Pulmonary Hypertension
Early Non-invasive Detection of CTEPH After Pulmonary Embolism
This is a prospective, international, multicenter outcome cohort study. This study starts at the moment patients visit the outpatient clinic 3 to 6 months after a diagnosis of acute PE as part of routine medical care.
- Trial name
- InShape2 (NCT02555137)
- Testing
- 'prediction score' and 'rule-out criteria'
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 424 people
- Sponsor
- Leiden University
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Cardiomyopathy, Cardiac Arrhythmia
RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators
If a surgical sponge is mistakenly left inside a patient's body after a surgical procedure, it can cause a serious infection. To prevent this from happening, a new device has been developed that uses radiofrequency (RF) signals…
- Conditions
- Cardiomyopathy, Cardiac Arrhythmia, Heart Failure, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- RF (NCT02111980)
- Testing
- RF Assure Scanning
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/ persistent or recurrent CTEPH after surgical treatment.
- Trial name
- JPMS-CTEPH (NCT02117791)
- Testing
- Riociguat (ADEMPAS, BAY63-2521)
- Where
- Japan
- Volunteers
- 1,298 people
- Sponsor
- Bayer
Venous Thromboembolism
Follow-up in Rivaroxaban Patients in Setting of Thromboembolism
In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes.
- Trial name
- FIRST (NCT02248610)
- Testing
- Non-interventional study
- Where
- 4 sites in United Kingdom
- Volunteers
- 1,343 people
- Sponsor
- King's College Hospital NHS Trust
Pulmonary Hypertension
CTEPH DIAGNOSIS Europe - MRI
Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH where positive findings are verified with catheter pulmonary angiography (CPA), or…
- Trial name
- NCT02791282
- Testing
- Index test: functional dynamic contrast enhanced (DCE)-MRI
- Where
- Germany
- Volunteers
- 1,080 people
- Sponsor
- Hannover Medical School
Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic
Medication Reconciliation in Pulmonary Hypertension
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex…
- Conditions
- Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic, Pulmonary Arterial Hypertension
- Trial name
- OPTICARE-HTP (NCT04744584)
- Testing
- Medication reconciliation
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Thromboembolic Pulmonary Hypertension
Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism
To address the knowledge gap that exists among providers resulting in underdiagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), the investigators have devised this 400-patient single-center Quality Improvement…
- Trial name
- CTEPH-DETECT (NCT03729544)
- Testing
- On-screen computerized decision support alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension
Long Term Outcomes of Venous Thromboembolism
This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC) rivaroxaban on the prevalence of…
- Conditions
- Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Venous Thrombosis
- Trial name
- LOVE (NCT02268630)
- Where
- 3 sites in Norway
- Volunteers
- 460 people
- Sponsor
- Ostfold Hospital Trust
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3)
Nailfold Capillaroscopy in PH
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3), Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT07768644
- Testing
- Standard of Care therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Glasgow
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Vasopressor Agents in Pulmonary Hypertension Crisis
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Hypertension, Pulmonary
- Trial name
- NCT07667829
- Testing
- Norepinephrine, Dopamine, Epinephrine
- Where
- 3 sites in China
- Volunteers
- 75 people
- Sponsor
- China National Center for Cardiovascular Diseases
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
- Trial name
- RIVERII (NCT04954742)
- Testing
- Riociguat
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heidelberg University
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Pulmonary Hypertension
RUS-registry of PH
Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the clinical course and disease management of PAH…
- Trial name
- NCT03707561
- Testing
- Right Heart Catheterization (RHC)
- Volunteers
- 200 people
- Sponsor
- Russian Cardiology Research and Production Center
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Potential outcomes after PE occur on a spectrum: complete recovery, exercise intolerance from deconditioning/anxiety, dyspnea from concomitant cardiopulmonary conditions, dyspnea from residual pulmonary vascular occlusion…
- Trial name
- ValidSEARCH (NCT05568927)
- Testing
- SEARCH algorithm
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Chronic Thromboembolic Pulmonary Hypertension
Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China
The Change Database is a prospective, observational multi-center disease registry, which will collect data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China.
- Trial name
- NCT05311072
- Testing
- pulmonary endarterectomy or balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
Chronic Thromboembolic Pulmonary Hypertension, Chronic Thromboembolic Disease
Chronic Thromboembolic Disease Registry
The goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (CTD) and/or chronic thromboembolic pulmonary hypertension (CTEPH).
- Trial name
- NCT05843500
- Testing
- Survey
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline